Dr. Lal PathLabs Limited (LALPATHLAB) AI Stock Analysis

• Market Cap: ₹218.91B
• Dividend Yield: 0.89%
• Average Volume (3M): 3.61K
• Price to Earnings (P/E): 68.4
• Beta (1Y): 0.63
• Revenue Growth: 10.80%
• EPS Growth: 32.79%
• Country: IN
• Employees: 4,099
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 6.70
• Shares Outstanding: 167,555,020
• 10 Day Avg. Volume: 2,182
• 30 Day Avg. Volume: 3,614
• PEG Ratio: 1.15
• Price to Book (P/B): 9.21
• Price to Sales (P/S): 8.13
• P/FCF Ratio: 38.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,577.00
• Price Target Upside: 7.06% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): 30.48
• Revenue Forecast (FY): ₹27.36B

• Rating: 66 Neutral
• Price Target: ₹1,416.00 ▼(-3.87% Downside)
• Action: Reiterated Date: 11/01/25
• Date: Action: Reiterated 11/01/25

Dr. Lal PathLabs' strong financial performance is the primary driver of its stock score, reflecting robust revenue growth and efficient cash management. However, the technical analysis indicates neutral to bearish momentum, and the high P/E ratio suggests overvaluation, which tempers the overall score.

Positive Factors

High Profitability

Sustained high gross and net margins indicate durable operational efficiency in lab operations and service delivery. Strong margins support reinvestment in network expansion, allow buffer against price pressure on routine tests, and underpin reliable earnings and cash generation over the medium term.

Negative Factors

Suboptimal Return on Equity

Room to improve ROE suggests the company may be capital intensive relative to returns or underutilizing equity. Over a multi-quarter horizon this can constrain shareholder returns unless management improves asset efficiency, raises margins further, or optimizes capital allocation.

Dr. Lal PathLabs Limited Business Overview & Revenue Model

Company Description

Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopatho...

Read more

Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopatho...

How the Company Makes Money

The company makes money primarily by charging fees for diagnostic tests and related laboratory services. Its core revenue stream comes from processing pathology and other clinical lab tests that are booked through its own patient service centers a...

Read more

The company makes money primarily by charging fees for diagnostic tests and related laboratory services. Its core revenue stream comes from processing pathology and other clinical lab tests that are booked through its own patient service centers a...

Dr. Lal PathLabs Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	26.00B	24.61B	22.27B	20.17B	20.87B	15.81B
Gross Profit	13.68B	14.24B	12.79B	11.25B	11.68B	8.77B
EBITDA	7.37B	6.58B	5.67B	4.41B	5.19B	3.99B
Net Income	5.35B	4.87B	3.58B	2.39B	3.45B	2.92B
Balance Sheet
Total Assets	29.59B	27.17B	24.56B	23.86B	23.53B	16.61B
Cash, Cash Equivalents and Short-Term Investments	13.02B	11.65B	9.43B	8.14B	6.82B	9.84B
Total Debt	2.55B	1.57B	2.47B	4.20B	5.32B	1.50B
Total Liabilities	5.37B	5.10B	5.71B	6.86B	8.10B	3.85B
Stockholders Equity	23.88B	21.73B	18.49B	16.66B	15.08B	12.45B
Cash Flow
Free Cash Flow	1.90B	5.25B	4.84B	4.11B	-294.49M	3.39B
Operating Cash Flow	3.24B	5.69B	5.35B	4.56B	4.47B	3.98B
Investing Cash Flow	-3.88B	-3.03B	-242.69M	-2.87B	-4.49B	-2.12B
Financing Cash Flow	-1.13B	-3.34B	-4.14B	-2.83B	1.36B	-1.39B

Dr. Lal PathLabs Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1472.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LALPATHLAB, the sentiment is Negative. The current price of 1472.95 is above the 20-day moving average (MA) of 1362.65, above the 50-day MA of 1390.14, and below the 200-day MA of 1494.03, indicating a bearish trend. The MACD of -24.90 indicates Positive momentum. The RSI at 36.25 is Neutral, neither overbought nor oversold. The STOCH value of 21.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LALPATHLAB.

Dr. Lal PathLabs Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIJAYA	75 Outperform	₹90.63B	63.11	―	0.20%	16.71%	13.92%
THYROCARE	69 Neutral	₹59.37B	61.22	―	0.68%	22.36%	52.00%
JLHL	67 Neutral	₹82.58B	53.67	―	0.14%	18.40%	7.30%
LALPATHLAB	66 Neutral	₹218.91B	68.44	―	0.89%	10.80%	32.79%
METROPOLIS	61 Neutral	₹93.02B	60.35	―	0.21%	15.41%	5.93%
KRSNAA	58 Neutral	₹18.61B	38.37	―	0.38%	11.51%	21.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%